Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025

Reuters03-28

Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025

Aethlon Medical outlined its Hemopurifier platform, an extracorporeal blood filtration device designed to capture enveloped viruses and extracellular vesicles using an affinity resin.
The company reported 173 treatments in 44 patients and said its clinical safety database shows a favorable safety profile.
Aethlon Medical said it has two FDA Breakthrough Device designations covering advanced or metastatic cancer and life-threatening viral infections with no approved therapies.
In its Australian oncology trial, the company said cohorts 1 and 2 are complete and cohort 3 is open for enrollment.
Key financial highlights cited cash of about USD 7.0 million and about 1.6 million shares outstanding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622871447?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 01:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622871447","market":"fut","top_or_hot":-1,"title":"Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Aethlon Medical outlined its Hemopurifier platform, an extracorporeal blood filtration device designed to capture enveloped viruses and extracellular vesicles using an affinity resin.\n        </li>\n<li>\n          The company reported 173 treatments in 44 patients and said its clinical safety database shows a favorable safety profile.\n        </li>\n<li>\n          Aethlon Medical said it has two FDA Breakthrough Device designations covering advanced or metastatic cancer and life-threatening viral infections with no approved therapies.\n        </li>\n<li>\n          In its Australian oncology trial, the company said cohorts 1 and 2 are complete and cohort 3 is open for enrollment.\n        </li>\n<li>\n          Key financial highlights cited cash of about USD 7.0 million and about 1.6 million shares outstanding.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-28 01:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Aethlon Medical outlined its Hemopurifier platform, an extracorporeal blood filtration device designed to capture enveloped viruses and extracellular vesicles using an affinity resin.\n        </li>\n<li>\n          The company reported 173 treatments in 44 patients and said its clinical safety database shows a favorable safety profile.\n        </li>\n<li>\n          Aethlon Medical said it has two FDA Breakthrough Device designations covering advanced or metastatic cancer and life-threatening viral infections with no approved therapies.\n        </li>\n<li>\n          In its Australian oncology trial, the company said cohorts 1 and 2 are complete and cohort 3 is open for enrollment.\n        </li>\n<li>\n          Key financial highlights cited cash of about USD 7.0 million and about 1.6 million shares outstanding.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8dGMcR:1","article_id":"2622871447","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622871447","pubTimestamp":1774631364,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aethlon Medical outlined its Hemopurifier platform, an extracorporeal blood filtration device designed to capture enveloped viruses and extracellular vesicles using an affinity resin.The company reported 173 treatments in 44 patients and said its clinical safety database shows a favorable safety profile.Aethlon Medical said it has two FDA Breakthrough Device designations covering advanced or metastatic cancer and life-threatening viral infections with no approved therapies.In its Australian oncology trial, the company said cohorts 1 and 2 are complete and cohort 3 is open for enrollment.Key financial highlights cited cash of about USD 7.0 million and about 1.6 million shares outstanding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","BK4082":"医疗保健设备","AEMD":"Aethlon Medical Inc","BK4568":"美国抗疫概念"},"translate_title":"Aethlon Medical发布血液净化器平台演示；截至2025年12月31日现金总额为700万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEMD":0.9},"content_text":"Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025\n    \n\n\n          Aethlon Medical outlined its Hemopurifier platform, an extracorporeal blood filtration device designed to capture enveloped viruses and extracellular vesicles using an affinity resin.\n        \n\n          The company reported 173 treatments in 44 patients and said its clinical safety database shows a favorable safety profile.\n        \n\n          Aethlon Medical said it has two FDA Breakthrough Device designations covering advanced or metastatic cancer and life-threatening viral infections with no approved therapies.\n        \n\n          In its Australian oncology trial, the company said cohorts 1 and 2 are complete and cohort 3 is open for enrollment.\n        \n\n          Key financial highlights cited cash of about USD 7.0 million and about 1.6 million shares outstanding.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622871447","isCrawlerRequest":true}